FDA Approves Novartis' Capmatinib, Foundation Medicine CDx for Metastatic NSCLC

May 06, 2020

|

NEW YORK – The US Food and Drug Administration on Wednesday approved capmatinib (Novartis' Tabrecta) for treatment of patients with metastatic non-small cell lung cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

FDA Approves Novartis' Capmatinib, Foundation Medicine CDx for Metastatic NSCLC

To read the full story....

Breaking News

FDA Issues EUA to Adaptive Biotechnologies Test for T-Cell Response to COVID-19

Cue Health Over-the-Counter COVID-19 Test Gets FDA Emergency Use Authorization

German Stores to Begin Selling COVID-19 Rapid Antigen Tests for Home Use

Abbott Gets FDA EUA for Test That Detects Coronavirus, Three Other Respiratory Infections

Illumina Receives Medical Device Registration in Russia for NextSeq 550 Dx Sequencer, Reagents

DermTech Q4 Revenues Up 31 Percent

Featured White Papers

What's Popular?

Dx Developers Hedge on SARS-Cov-2 Rapid Antigen Tests, Citing Conflicting FDA Messages

Cue Health Over-the-Counter COVID-19 Test Gets FDA Emergency Use Authorization

Abbott Gets FDA EUA for Test That Detects Coronavirus, Three Other Respiratory Infections

Abbott SARS-CoV-2 IgG Antibody Test Receives Emergency Use Authorization from FDA

Luminex Obtains FDA Emergency Use Authorization for Expanded Respiratory Panel With SARS-CoV-2

Sponsorships